Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. Belgium
  4. Euronext Bruxelles
  5. Hyloris Pharmaceuticals SA
  6. Company
    HYL   BE0974363955

HYLORIS PHARMACEUTICALS SA

(HYL)
  Report
Real-time Euronext Bruxelles  -  03:00 2022-10-06 am EDT
12.74 EUR   +1.11%
09/06Pleco Therapeutics B.V. announced that it has received €4.6 million in funding from Hyloris Pharmaceuticals SA, Oost NL BV
CI
09/06Pleco Therapeutics B.V. announced that it has received funding from Oost NL BV, Hyloris Pharmaceuticals SA
CI
09/01Hyloris Pharmaceuticals Reports 2022 Half-Year Results and Provides Corporate Update
GL
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
Business Summary
Logo Hyloris Pharmaceuticals SA
Hyloris Pharmaceuticals SA is a specialty biopharma company identifying and unlocking hidden potential in existing medications for the benefit of patients and the healthcare system. Hyloris applies its knowhow and technological innovations to existing pharmaceuticals and has built a broad proprietary product pipeline that has the potential to offer significant advantages over currently available alternatives. Hyloris Pharmaceuticals SA currently has two, partnered commercial-stage products, Sotalol IV for the treatment of atrial fibrillation, and Maxigesic® IV, a non-opioid analgesic for the treatment of pain. The Company's development strategy primarily focuses on the FDA's 505(b)2 regulatory pathway, which is specifically designed for pharmaceuticals for which safety and efficacy of the molecule has already been established.
Sales per Business
20202021Delta
Pharmaceuticals0.18100%3.10100% +1669.14%
EUR in Million
Sales per region
20202021Delta
Belgium0.18100%3.10100% +1669.14%
EUR in Million
Managers
Name Title Age Since
Stijn van Rompay Chief Executive Officer & Executive Director 45 2021
Jean-Luc Vandebroek Chief Financial Officer 50 2021
Dietmar Aichhorn, Dr. Chief Operating Officer - 2020
Marieke Vermeersch VP-Investor Relations & Corporate Communications - 2021
Thomas Jacobsen Director & Chief Business Development Officer 47 2021
Koenraad van der Elst Chief Legal Officer 60 2020
Members of the board
Name Title Age Since
Stefan Yee Chairman 59 2019
Marc Foidart Independent Director - 2020
Carolyn J. Myers, Dr. Independent Director 63 2020
James Charles Gale Independent Director 71 2020
Chris Buyse Independent Director 56 -
Stijn van Rompay Chief Executive Officer & Executive Director 45 2021
Thomas Jacobsen Director & Chief Business Development Officer 47 2021
Leon van Rompay Non-Executive Director 72 2020
Equities
Vote QuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 25,832,632 13,485,387 52.2% 0 0.0% 52.2%
Shareholders
NameEquities%
Stijn van Rompay 7,080,658 25.3%
Thomas Jacobsen 3,626,090 13.0%
Bart Versluys 1,792,945 6.40%
Nick Reunbrouck 1,669,663 5.96%
Pieter van Rompay 948,733 3.39%
Saffelberg Investments NV 854,931 3.05%
Mandarine Gestion SA 72,500 0.26%
Koenraad van der Elst 27,443 0.098%
Degroof Petercam Asset Management SA 16,130 0.058%
Claresco Finance SA 2,000 0.0071%
Markets and indexes
- Compartiment B
- BEL Small / Next Biotech, PEA
Stock Exchange Codes
- Bloomberg Code :  
- Reuters Code :  HYL.BX
- Datastream Code :  
Company contact information
Hyloris Pharmaceuticals SA
Boulevard Gustave Kleyer 17
BE-4000 Rocourt, Liège

Phone : +32 4346 02 07
Fax :
web site : http://www.hyloris.com
Brand Portfolio
In partnership withAllbrands.markets
More brands of Hyloris Pharmaceuticals SA
Sector Other Pharmaceuticals
1st jan.Capi. (M$)
HYLORIS PHARMACEUTICALS SA-27.17%333
JOHNSON & JOHNSON-3.48%435 445
ELI LILLY AND COMPANY19.43%313 453
ROCHE HOLDING AG-12.23%279 092
ABBVIE INC.4.87%251 052
PFIZER, INC.-25.28%249 525
NOVO NORDISK A/S6.91%238 512
MERCK & CO., INC.15.33%223 917
ASTRAZENECA PLC14.59%176 480
NOVARTIS AG-4.12%171 494
BRISTOL-MYERS SQUIBB COMPANY14.60%152 052
AMGEN INC.3.93%124 650
SANOFI-9.27%99 997
GILEAD SCIENCES, INC.-9.86%81 857
GSK PLC-19.14%61 509
DAIICHI SANKYO CO., LTD.44.85%56 246
BAYER AG3.51%47 628
CHUGAI PHARMACEUTICAL CO., LTD1.47%43 177
TAKEDA PHARMACEUTICAL COMPANY LIMITED23.49%41 630
JIANGSU HENGRUI MEDICINE CO., LTD.-30.78%31 468
ASTELLAS PHARMA INC.5.05%24 803